Long-Term Use of Relacorilant for Cushing Syndrome
Recruiting at 78 trial locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Corcept Therapeutics
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Research Team
KA
Katherine Araque, MD, MSCR
Principal Investigator
Corcept Therapeutics
Eligibility Criteria
This trial is for patients with Cushing Syndrome who have finished a previous Corcept-sponsored relacorilant study and took their medication at least 80% of the time. They should not have dropped out early, nor should they have uncontrolled thyroid issues, poorly controlled high blood pressure, or severe kidney failure.Inclusion Criteria
You have participated in a previous study on relacorilant for Cushing syndrome and followed the dosing schedule at least 80% of the time.
The doctor believes it is beneficial for you to keep taking relacorilant.
Exclusion Criteria
My thyroid condition is not under control.
My high blood pressure is not well-managed.
My kidney function is severely reduced.
See 1 more
Treatment Details
Interventions
- Relacorilant (Corticosteroid)
Trial OverviewThe trial is testing the long-term safety of a drug called relacorilant in those with endogenous Cushing Syndrome. It's an open-label extension which means everyone knows they are getting relacorilant and there's no placebo group.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: relacorilant (CORT125134)Experimental Treatment1 Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corcept Therapeutics
Lead Sponsor
Trials
72
Recruited
7,700+
Dr. Joseph K. Belanoff
Corcept Therapeutics
Chief Executive Officer since 2014
MD from Stanford University
Dr. William Guyer
Corcept Therapeutics
Chief Medical Officer since 2021
PharmD